Drug Type Enzyme |
Synonyms- |
Target |
Action stimulants |
Mechanism Alkaline phosphatase stimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Organ Failure | Phase 2 | Belgium | 01 Sep 2004 | |
Multiple Organ Failure | Phase 2 | Netherlands | 01 Sep 2004 | |
Sepsis | Phase 2 | Belgium | 01 Sep 2004 | |
Sepsis | Phase 2 | Netherlands | 01 Sep 2004 |
Phase 2 | Oxygen radical damage adenosine | creatinine | cystatin-C | 11 | bgnqkqjzdq(hmwdccaidq) = There were no adverse events observed in the bRESCAP group. wjmvzmociq (rpskvwqfpg ) | Negative | 03 May 2022 | ||
Placebo | |||||||
Not Applicable | - | - | giupzzrsff(kksiaopbyr) = psywploiye hubzpyejwb (sdzreogpwu ) | - | 13 Jun 2018 | ||
Phase 2 | Acute kidney injury due to sepsis renal KIM-1 | 36 | Alkaline Phosphatase | agebvhnufo(ukaydmygbn) = ilvylcptvu jibsuxwbhj (tzdgjzsduo ) | Positive | 16 Nov 2010 | |
Alkaline Phosphatase (Placebo) | agebvhnufo(ukaydmygbn) = bakimupxxt jibsuxwbhj (tzdgjzsduo ) |